Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.64 |
| ▸ | HTR2C | P28335 | 6/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B | O95264 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | HTR1F | P30939 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL798115 | 0.99 | HTR2C (0.65) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL1495 | 0.80 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL183226 | 0.80 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL30057954 | 0.80 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL29349412 | 0.80 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| SCHEMBL8714246 | 0.79 | HTR2A (0.61) | HTR2AHTR2CHTR1ACYP2D6CYP1A2 | |
| SCHEMBL28582265 | 0.79 | MTNR1A (0.68) | HTR1ACYP2D6HTR2BCYP1A2CYP3A4 | |
| Serotonin SCHEMBL25341783 | 0.79 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL396997 | 0.79 | HTR2C (0.97) | HTR2AHTR2CHTR1ACYP2D6HTR2B | |
| Serotonin SCHEMBL8208967 | 0.79 | HTR2C (1.00) | HTR2AHTR2CHTR1ACYP2D6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116133625-A | Vascular compression devices and methods for delivering vascular compression therapy to patients undergoing chemotherapy therapy | 广州芙力丝医疗科技开发有限公司 | 2023-05-16 | — | — | CN | claimed |
| EP-4171459-A1 | VASOCOMPRESSION DEVICES AND METHODS OF DELIVERING VASOCOMPRESSION THERAPY TO A PATIENT UNDERGOING CHEMOTHERAPY TREATMENT | Guangzhou Follisave Technology Development Ltd. (CN) | 2023-05-03 | — | — | EP | claimed |
| WO-2021262957-A1 | VASOCOMPRESSION DEVICES AND METHODS OF DELIVERING VASOCOMPRESSION THERAPY TO A PATIENT UNDERGOING CHEMOTHERAPY TREATMENT | BELSON AMIR (US) | 2021-12-30 | — | — | WO | claimed |
| US-20210315834-A1 | TREATMENT OF ALOPECIA | SOL-GEL TECHNOLOGIES LTD. (IL) | 2021-10-14 | — | — | US | claimed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | claimed |
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20240158339-A1 | TYRAMINE CONTAINING HYDROXYCINNAMIC ACID AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2024-05-16 | — | — | US | disclosed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | disclosed |
| CN-117897206-A | Curing ring seal | 科利耳有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240100061-A1 | Compositions of Iboga Alkaloids and Methods of Treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240100062-A1 | Methods of Treatment With an Iboga Alkaloid | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024063349-A1 | SUSTAINED-RELEASE MOSAPRIDE FORMULATION | 한국유나이티드제약 주식회사 | 2024-03-28 | — | — | WO | disclosed |
| EP-0993301-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0993301-A4 | COCAINE RECEPTOR BINDING LIGANDS | RES TRIANGLE INST (US) | 2000-04-19 | — | — | EP | disclosed |
| US-5879682-A | Aframonum seeds for improving penile activity | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 1999-03-09 | — | — | US | disclosed |
| US-5798382-A | TREATING SEROTONERGIC NEURON-RELATED DISEASES | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-08-25 | — | — | US | disclosed |
| US-5792791-A | FOR PREVENTION AND TREATMENT OF SEROTONERGIC NEURON-RELATED DISEASES; HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-08-11 | — | — | US | disclosed |
| WO-1998007427-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 1998-02-26 | — | — | WO | disclosed |
| US-4704394-A | SEROTONIN ANTAGONISTS | TECHNOLOGY UNLIMITED, INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4175084-A | AND AN N-ACYL ASPARTIC ACID CARRIER, FOR PSYCHOLOGICAL DISORDERS, LEARNING ENHANCEMENT AND SLEEP INDUCTION | SENTRALINSTITUTT FOR INDUSTRIELL FORSKNING (NO) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100061-A1 | Compositions of Iboga Alkaloids and Methods of Treatment | GAP43, PYGB, INA | HTR2A 21/4885HTR2C 71/4885HTR1A 26/4885 |
| US-20240158339-A1 | TYRAMINE CONTAINING HYDROXYCINNAMIC ACID AMIDE DERIVATIVES AND METHODS OF USE THEREOF | GLS2, LIPC, AADAT | HTR2A 74/4885HTR2C 101/4885HTR1A 367/4885 |
| US-20240100062-A1 | Methods of Treatment With an Iboga Alkaloid | INA, GAP43, PYGB | HTR2A 9/4885HTR2C 66/4885HTR1A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.